Capital Fund Management S.A. bought a new stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 123,005 shares of the company's stock, valued at approximately $2,634,000. Capital Fund Management S.A. owned 0.23% of CareDx as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Thompson Davis & CO. Inc. lifted its stake in CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after acquiring an additional 950 shares in the last quarter. Legal & General Group Plc grew its position in CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after purchasing an additional 1,118 shares in the last quarter. Principal Financial Group Inc. increased its stake in CareDx by 6.5% in the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after buying an additional 1,151 shares during the period. Plato Investment Management Ltd lifted its position in CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after buying an additional 1,370 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of CareDx by 1.8% during the 4th quarter. Rhumbline Advisers now owns 81,201 shares of the company's stock valued at $1,738,000 after acquiring an additional 1,451 shares in the last quarter.
CareDx Trading Down 3.3 %
CDNA traded down $0.60 during midday trading on Friday, reaching $17.62. The company's stock had a trading volume of 537,147 shares, compared to its average volume of 853,578. The company has a fifty day simple moving average of $19.73 and a 200 day simple moving average of $22.26. The stock has a market cap of $976.61 million, a P/E ratio of -6.53 and a beta of 2.18. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84.
CareDx (NASDAQ:CDNA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. Sell-side analysts expect that CareDx, Inc will post -0.9 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on CDNA shares. Stephens reiterated an "overweight" rating and set a $40.00 price objective on shares of CareDx in a report on Thursday, February 27th. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and reduced their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. The Goldman Sachs Group dropped their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, HC Wainwright decreased their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, CareDx has an average rating of "Moderate Buy" and a consensus price target of $30.33.
Read Our Latest Research Report on CareDx
About CareDx
(
Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Stories
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
